Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis

Abstract

In this study, we investigate the veliparib‑induced toxicity in cancer patients. Databases were searched for RCTs treated with veliparib. We found veliparib could increase the risk of hematologic and gastrointestinal toxicities. Anemia, neutropenia, thrombocytopenia, and nausea were the most common toxicities. Patients diagnosed with gastrointestinal tumors tend to have a higher risk of high-grade neutropenia; patients in the first-line setting tend to have a higher risk of high-grade anemia and neutropenia than those in the ≥ second line setting. Patients receiving higher dosage of veliparib tend to have a higher risk of all-grade anemia. Veliparib could also increase the risk of insomnia, myalgia, pneumonia, dyspnea, hyponatremia, and fatigue.

Keywords:

• Veliparib
• adverse events
• cancer
• meta-analysis
• systematic review

Authors’ contributions

Peirong Wang and Xianhua Zhou conceived and designed the study. Xianhua Zhou and Xiaolong Xie wrote the main manuscript text. Peirong Wang and Ruizhen Zhao extracted and reviewed the data. Xiaohui Jin and Ruizhen Zhao analyzed the data.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Additional information

Funding

This work is supported by "Xinglin Scholar" of Chengdu University of Traditional Chinese Medicine (YYZX2022016); research project of teaching reform of Chengdu University of Traditional Chinese Medicine (JDJG-202121963); Sichuan Traditional Chinese Medicine Culture Collaborative Development Research Center (2023XT17); China Unearthed Medical Literature and Cultural Relics Research Center (CTWX2205); Sichuan Provincial Administration of Traditional Chinese Medicine (2022CP7657).